Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase a inhibitors

被引:62
作者
Chimenti, F
Bolasco, A
Manna, F
Secci, D
Chimenti, P
Granese, A
Befani, O
Turini, P
Cirilli, R
La Torre, F
Alcaro, S
Ortuso, F
Langer, T
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biologi, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy
[3] Univ Roma La Sapienza, Ctr Biol Mol, CNR, I-00185 Rome, Italy
[4] Ist Super Sanita, Lab Chim Farm, I-00161 Rome, Italy
[5] Univ Catanzaro Magna Graecia, Dipartimento Sci Farm Biol Complesso Nini Barbier, I-88021 Roccelletta Di Borgia, CZ, Italy
[6] Univ Innsbruck, Inst Pharm, Dept Pharmaceut Chem, A-6020 Innsbruck, Austria
关键词
monoamine oxidase; reversible monoamine oxidase-A inhibitors; selective monoamine oxidase-A inhibitors; (1H)-pyrazole derivatives; 3D-QSAR;
D O I
10.2174/092986706776872907
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present report provides a extended study of the chemistry, the inhibitory activity against monoamino oxidases (MAO), and molecular modeling including the 3D-QSAR hypothesis of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives. Four series of about eighty novel pyrazoline derivatives were prepared and investigated for their ability to inhibit the activity of the A and B isoforms of MAO selectively. Most of the new synthesized compounds proved more reversible, potent, and selective inhibitors of MAO-A than of MAO-B, and could be taken into account to develop the search further in this field, knowing that reversible and selective MAO-A inhibitors are used as antidepressant and antianxiety drug. The 30 most active compounds show inhibitory activity on MAO-A in the 8.6 x 10(-8)-9.0 x 10(-9)M range. Moreover, it should be pointed out that for most of them a high IC50 >= 10(-9)M value is associated with a high A-selectivity (Selectivity Index MAO-B/MAO-A in the 10,000-16,250 range). Furthermore, due to the presence of a chiral centre at the C5 position of the pyrazole moiety, we performed the semi-preparative chromatographic enantioseparation of the most potent, selective, and chiral compounds. The separated enantiomers were then submitted to in vitro biological evaluation, and from the results of these experiments it has been possible to point out a difference in inhibiting the two isoforms selectively between the racemic mixture and the single enantiomers. The molecular modeling work was carried out combining the Glide docking approach with CoMFA with the aim to rationalize the structure-activity relationships of each pyrazoline inhibitor toward MAO-A and MAO-B isoforms and to derive a suitable selectivity model.
引用
收藏
页码:1411 / 1428
页数:18
相关论文
共 73 条
[41]   Inhibitory effect of 1,3,5-triphenyl-4,5-dihydro-(1H)-pyrazole derivatives on activity of amine oxidases [J].
Manna, F ;
Chimenti, F ;
Bolasco, A ;
Bizzarri, B ;
Befani, O ;
Pietrangeli, P ;
Mondovi, B ;
Turini, P .
JOURNAL OF ENZYME INHIBITION, 1998, 13 (03) :207-+
[42]   A SENSITIVE FLUOROMETRIC ASSAY FOR SERUM MONOAMINE-OXIDASE WITH KYNURAMINE AS SUBSTRATE [J].
MATSUMOTO, T ;
SUZUKI, O ;
FURUTA, T ;
ASAI, M ;
KUROKAWA, Y ;
NIMURA, Y ;
KATSUMATA, Y ;
TAKAHASHI, I .
CLINICAL BIOCHEMISTRY, 1985, 18 (02) :126-129
[43]   ANTITUBERCULAR SUBSTANCES .2. SUBSTITUTION PRODUCTS OF ISONICOTINIC HYDRAZIDE [J].
MCMILLAN, FH ;
LEONARD, F ;
MELTZER, RI ;
KING, JA .
JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION-SCIENTIFIC EDITION, 1953, 42 (08) :457-464
[44]   SYNTHESIS OF 2', 6'-DIHYDROXYCHALCONES BY USING TETRAHYDROPYRAN-2-YL AND TRIALKYLSILYL PROTECTIVE GROUPS - THE CRYSTAL-STRUCTURE DETERMINATION OF 2',6'-DIHYDROXY-2,4,6-TRIMETHOXYCHALCONE [J].
MILES, CO ;
MAIN, L ;
NICHOLSON, BK .
AUSTRALIAN JOURNAL OF CHEMISTRY, 1989, 42 (07) :1103-1113
[45]   MACROMODEL - AN INTEGRATED SOFTWARE SYSTEM FOR MODELING ORGANIC AND BIOORGANIC MOLECULES USING MOLECULAR MECHANICS [J].
MOHAMADI, F ;
RICHARDS, NGJ ;
GUIDA, WC ;
LISKAMP, R ;
LIPTON, M ;
CAUFIELD, C ;
CHANG, G ;
HENDRICKSON, T ;
STILL, WC .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1990, 11 (04) :440-467
[46]  
MONDOVI B, 1985, STRUCTURE FUNCTION A
[47]   A REVERSIBLE MONOAMINE-OXIDASE INHIBITOR, TOLOXATONE - SPECTROPHOTOMETRIC AND MOLECULAR-ORBITAL STUDIES OF THE INTERACTION WITH FLAVIN ADENINE-DINUCLEOTIDE (FAD) [J].
MOUREAU, F ;
WOUTERS, J ;
VERCAUTEREN, DP ;
COLLIN, S ;
EVRARD, G ;
DURANT, F ;
DUCREY, F ;
KOENIG, JJ ;
JARREAU, FX .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1994, 29 (04) :269-277
[48]   A REVERSIBLE MONOAMINE-OXIDASE INHIBITOR TOLOXATONE - COMPARISON OF ITS PHYSICOCHEMICAL PROPERTIES WITH THOSE OF OTHER INHIBITORS INCLUDING BROFAROMINE, HARMINE, R40519 AND MOCLOBEMIDE [J].
MOUREAU, F ;
WOUTERS, J ;
DEPAS, M ;
VERCAUTEREN, DP ;
DURANT, F ;
DUCREY, F ;
KOENIG, JJ ;
JARREAU, FX .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1995, 30 (11) :823-838
[49]   A REVERSIBLE MONOAMINE-OXIDASE INHIBITOR, TOLOXATONE - STRUCTURAL AND ELECTRONIC-PROPERTIES [J].
MOUREAU, F ;
WOUTERS, J ;
VERCAUTEREN, DP ;
COLLIN, S ;
EVRARD, G ;
DURANT, F ;
DUCREY, F ;
KOENIG, JJ ;
JARREAU, FX .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1992, 27 (09) :939-948
[50]   Progress in monoamine oxidase (MAO) research in relation to genetic engineering [J].
Nagatsu, T .
NEUROTOXICOLOGY, 2004, 25 (1-2) :11-20